Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. is a U.S.-based clinical-stage biotechnology company focused on developing RNAi-based immuno-oncology therapies. Through its subsidiary MirImmune, LLC, the company advances INTASYL drug candidates such as PH-762 and PH-894 for potential use in cancer treatment.

17.81

— Phio Pharmaceuticals Corp.
	%
RNAi therapeutic platform	40% INTASYL-based RNA interference technology used to silence target genes in immune and cancer cells.
Clinical-stage oncology candidates	35% Lead and pipeline drug candidates being developed for immuno-oncology applications.
Preclinical development services	15% IND-enabling studies, translational research, and early-stage development work.
Intellectual property portfolio	10% Patents and pending applications covering compounds, technologies, and geographic protection.

Phio does not sell commercial products today; its primary counterparties are clinical collaborators, research vendors,...

Clinical development partnersprimary
Research organizations and collaborators that support preclinical studies, assay work, and trial execution.
Regulatory agenciesprimary
U.S. and other regulators that review IND submissions and clinical packages for PH-762 and PH-894.
Future oncology prescribersemerging
Oncologists and cancer centers that would use approved therapies if the pipeline reaches commercialization.
Capital providersprimary
Equity and debt investors that fund ongoing R&D and public-company operations.

Phio is headquartered in the United States and concentrates its development and patent activity there, while also...

•Headquartered and primarily operated in the United States
•U.S. is the main focus for clinical development and IND activity
•Patent coverage extends to Canada, Europe, Japan, and other markets
•International IP matters for partnering and future commercialization
•No revenue geography disclosed because the company is pre-commercial

Phio’s strategy centers on advancing its lead immuno-oncology candidate PH-762 while continuing preclinical work on...

Advance PH-762 clinical developmentshort-term

The lead candidate is the main path to value creation and potential partnering.

Prepare PH-894 for IND submissionmedium-term

Broadens the pipeline and creates a second development asset.

Protect and rationalize IP portfoliomedium-term

Patent coverage supports exclusivity and future licensing leverage.

Secure development fundingshort-term

Clinical biotechnology requires ongoing external capital before product revenue exists.

Phio faces the typical risks of a pre-commercial biotech company: clinical and regulatory uncertainty, dependence on...

critical

Clinical development failure

Drug candidates may not show sufficient efficacy or safety in preclinical or clinical testing.

Scope: PH-762, PH-894
Materiality: high

high

Nasdaq continued listing compliance

The company must maintain minimum bid price and equity requirements to remain listed.

Scope: Nasdaq Capital Market listing
Materiality: high

high

Financing dependence

Operations are funded primarily through external capital until any product revenue exists.

Scope: Equity, debt, strategic funding
Materiality: high

medium

Supply and trade policy disruption

Research and development inputs may be delayed or become more expensive.

Scope: Preclinical and clinical development operations
Materiality: medium

Research and development accruals

Affects operating expense timing and liabilities

Stock-based compensation

Affects operating expenses and equity

Going-concern assessment

Affects disclosure and investor perception

Equity financing and reverse stock splits

Affects dilution and comparability

Phio Pharmaceuticals Corp.

Clinical development failure

Nasdaq continued listing compliance

Financing dependence

Supply and trade policy disruption

Xilio Therapeutics, Inc.

IO Biotech, Inc.

INOVIO PHARMACEUTICALS, INC.

Oncotelic Therapeutics, Inc.

Inmune Bio, Inc.

INTENSITY THERAPEUTICS, INC.